Form 4: AtriCure's Chief Legal Officer, Karl S. Dahlquist, Sells Shares Under 10b5-1 Trading Plan

Karl S. Dahlquist, Chief Legal Officer of AtriCure, Inc., sold 8,231 shares of common stock on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 5, 2024, Karl S. Dahlquist, the Chief Legal Officer of AtriCure, Inc. (ATRC), sold 8,231 shares of the company's common stock.
• The sale was executed under a 10b5-1 trading plan adopted on February 24, 2023.
• The shares were sold at a weighted average price of $37.36, with individual transaction prices ranging from $36.57 to $37.74 per share.
• Following the transaction, Dahlquist directly owns 52,839 shares of AtriCure common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading. The impact on the stock price is usually minimal unless the sale is unusually large or coincides with other significant news.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates